Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Lichao Liu, Ruihao Huang, Yongxian Hu, Sanfang Tu, Na Wang, Hai Yi, Qiuying Gao, Jian Zhou, Xiaoqi Wang, Cheng Zhang, Xi Zhang

Blood (2024) 144 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2024-207676

Published: 2024

Journal Articles

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Chuting Yang, Rui Huang, Danian Nie, Yiqing Li, Yuming Zhang, Honghua He, Chaoyang Song, Sanfang Tu, Yaling Zheng, Xuan Zhou, Jie Chen, Hui Zeng, Yuhua Li

Blood (2024) 144 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2024-201586

Published: 2024

Journal Articles

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Ingrid Glimelius, Won Seog Kim, Ewa Paszkiewicz-Kozik, Daniel Ernst, Reid W. Merryman, Claudia Moreira, Sanfang Tu, Yixin Ren, Katherine Ryland, Uzor C. Ogbu, Pier Luigi Zinzani

Blood (2024) 144 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2024-205897

Published: 2024

Journal Articles

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Shaojie Wu, Yanni Deng, Mingyao Lai, Sanfang Tu, Linbo Cai, Yuhua Li

Blood (2024) 144 (Supplement 1): 4457.

https://doi.org/10.1182/blood-2024-200645

Published: 2024

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3492.

https://doi.org/10.1182/blood-2023-186888

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)

Hongyan Tong, Sujun Gao, Wei Yang, Junmin Li, Qingsong Yin, Xingli Zhao, Xiaojing Yan, Sanfang Tu, Fei Li, Haiping Yang, Ronghua Hu, Shaoyuan Wang, Zheng Dong, Yixuan Yang, Zhenjiu Wang, Qiying Lu, Wenzhi Tian, Zhijian Xiao, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 1859.

https://doi.org/10.1182/blood-2023-181501

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Blood (2023) 142 (Supplement 1): 320.

https://doi.org/10.1182/blood-2023-174420

Published: 2023

Journal Articles

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Sanfang Tu, Lijuan Zhou, Rui Huang, Yanjie He, Xuan Zhou, Jilong Yang, Yuxing Hu, Honghao Zhang, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 3488.

https://doi.org/10.1182/blood-2023-186308

Published: 2023

Journal Articles

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Blood (2023) 142 (Supplement 1): 4263.

https://doi.org/10.1182/blood-2023-177568

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Langqi Wang, Jilong Yang, Bo Jin, Bo Wang, Lijuan Zhou, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Sanfang Tu, Yuhua Li

Blood (2023) 142 (Supplement 1): 4841.

https://doi.org/10.1182/blood-2023-186439

Published: 2023

Journal Articles

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Lijuan Zhou, Rui Huang, Xuan Zhou, Jilong Yang, Meifang Li, Bo Jin, Langqi Wang, Yaqi Zhuo, Huifang Chen, Lung-Ji Chang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6884.

https://doi.org/10.1182/blood-2023-186622

Published: 2023

Journal Articles

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

Shaojie Wu, Sanfang Tu, Zhenjun Zhou, Xinlin Sun, Anqin Wu, Lei Wang, Yuhua Li

Blood (2023) 142 (Supplement 1): 6322.

https://doi.org/10.1182/blood-2023-181471

Published: 2023

Journal Articles

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Sanfang Tu, Kecheng Wang, Chaoyang Song, Xuan Zhou, Dan Xiong, Guinian Huang, Jia Feng, Jilong Yang, Bo Jin, Bo Wang, Langqi Wang, Yaqi Zhuo, Huifang Chen, Yuhua Li

Blood (2023) 142 (Supplement 1): 5818.

https://doi.org/10.1182/blood-2023-184746

Published: 2023

Journal Articles

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Dan Xu, Ying Yang, Zhao Yin, Sanfang Tu, Danian Nie, Qixin Sun, Zhengqian Huang, Yu Zhang, Guopan Yu

Blood (2022) 140 (Supplement 1): 9097.

https://doi.org/10.1182/blood-2022-159589

Published: 2022

Journal Articles

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Rui Zhang, MSc, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Rui Huang, MD& PhD, Xun Lai, MD, Leping Zhang, MD PhD, Eugene E. Zvonkov, MD PhD, Valeriy G. Savchenko, MD PhD, Nelly G Gabeeva, PhD, Yuchen Liu, MSc, Yuchen Li, MSc, Cheng Jiao, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Hongyu Zhang, MD PhD, Wenli Zhang, MD, Lung-Ji Chang, PhD

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-141515

Published: 2020

Journal Articles

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-141531

Published: 2020

Journal Articles

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Sanfang Tu, MD PhD, Lan Deng, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Jilong Yang, MD, Weijun Zhou, MD PhD, Meifang Li, MD PhD, Chunyan Yue, MD, Shaojie Wu, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2018-99-118526

Published: 2018

Journal Articles

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Lan Deng, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Weijun Zhou, MD PhD, Jilong Yang, MD, Chunyan Yue, MD, Anqin Wu, Meifang Li, MD PhD, Zhenling Guo, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 2696.

https://doi.org/10.1182/blood-2018-99-118928

Published: 2018

Journal Articles

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Sanfang Tu, MD PhD, Rui Huang, MD PhD, Xuan Zhou, MD, Yanjie He, MD PhD, Zhao Liang, MD PhD, Lei Wang, MD PhD, Lung-Ji Chang, PhD, Yuhua Li, MD PhD

Blood (2018) 132 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2018-99-117694

Published: 2018

Journal Articles

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Lung-Ji Chang, PhD, Yuhua Li, MD& PhD, Sanfang Tu, MD& PhD, Xun Lai, MD, Rui Huang, MD& PhD, Shih-Ting Tsao, MSc, Yu-Chen Liu, MSc, Rui Zhang, MSc, Lan Deng, MDPhD, Xuan Zhou, MD, Hongyu Zhang, PhD MD, Wenli Zhang, MD, Yuchen Li, MSc

Blood (2018) 132 (Supplement 1): 225.

https://doi.org/10.1182/blood-2018-99-114396

Published: 2018

NARROW

Comparison of the Efficacy and Adverse Effects of Recipient-Derived Versus Donor-Derived CAR-T Cell Therapy for Post-Transplant Relapse in B-ALL

Updated Results from a Phase Ⅱ Clinical Trial：Safety and Efficacy of Azacitidine and Chidamide Maintenance after Allogeneic Hematopoietic Stem Cell Transplantation for Patients with High-Risk Acute Myeloid Leukemia

Zilovertamab Vedotin Monotherapy for Patients with Relapsed or Refractory Mantle Cell Lymphoma: Cohort a of the Multicenter, Open-Label, Phase 2 Waveline-006 Study

Retrospective Analysis of 118 Cases of Primary Central Nervous System Lymphoma

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy with Dual Targeting of CD19 and CD70 to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Chronic Myelomonocytic Leukemia (CMML)

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Dendritic Cell Vaccines Extend CD19 CAR-T Cell Persistence and Improve the Outcomes in Refractory/Relapsed Adult B-ALL

Venetoclax Plus Azacitadine for Middle Aged and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: Interim Analysis of a Prospective, Multicenter, Single-Arm, Phase 2 Trial

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD22 to Treat Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults

Efficacy and Safety of Orelabrutinib-Containing Regime (TORM) As First-Line Therapy in Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis

Safety and Efficacy of Single Cycle Blinatumomab Plus VP Chemotherapy for High Tumor Burden Acute Lymphoblastic Leukemia in Adults

Gene Mutation and MRD-Directed Risk Stratification Treatment Improves Long Term Survival of the Patients with AML1-ETO-Positive AML

Improved Safety and Efficacy of a Multi-Target Chimeric Antigen Receptor Modified T Cell Therapy (4SCAR2.0) Against Relapsed or Refractory Lymphomas

CAR2.0 Therapy for the Management of Post-Transplantation Relapse of B-Cell Acute Lymphoblastic Leukemia

A Novel Chimeric Antigen Receptor T Cells Therapy Strategy That Dual Targeting CD19 and CD123 to Treat Relapsed Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Therapy of 4s Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival with No Severe CRS or Cres in Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia

Combination of CD19 and CD70 Specific Chimeric Antigen Receptor T Cells Achieves Long-Term Disease-Free Survival in Relapsed and Refractory Primary Central Nervous System Diffuse Large B Cell Lymphoma

Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only